Eli Lilly buys a private biotechnology company, Disarm Therapeutics, which has discovered new powerful SARM1 inhibitors and conducts their preclinical research. They are a new treatment method for patients with peripheral neuropathy and other neurological diseases. Disarm shareholders will receive an advance of $135 million and will be eligible to receive up to $1.225 billion more, depending on the success of further drug inhibitor development.